

Spectrophotometric Method Development and Validation of Levosulpiride in Bulk and Pharmaceutical Formulations.

V.HariBhaskar, Sk.Salma, G.BuelaPriyanka & A.Ramesh

Abstract

A validated UV-Visible spectrophotometer technique was used to assess the levosulpiride concentration in both bulk and pharmaceutical formulation. In 0.1 N HCl, the maximum wavelength (λ_{max}) measured for levosulpiride was 288.1 nm. Between 6 and 36 μ g/ml, the medication demonstrates linearity. The standard graph showed a correlation value of 0.999. The suggested procedure produced test percentages of commercial formulations that were consistent with the claims made on the label. A recovery experiment was conducted at three distinct levels (80%, 100%, and 120% recovery) to verify the method's accuracy. The percentage recovery ranged from 98.00% to 102.00%. The method's accuracy and repeatability were confirmed by the low % RSD. Experimentation with the method's repeatability, precision, and intra- and inter-day fluctuations showed that it agreed well with %RSD. The suggested approach was determined to be strong and resilient. Levosulpiride, both in bulk and medicinal dose form, may be routinely analyzed using the aforementioned approach.

Keywords:Area under the curve, validation, levosulpiride

Introduction

The anti-psychotic Levo-isomer of sulpiride is known as levosulpiride. Peptic ulcers, anxiety problems, and schizophrenia are among the conditions that it helps alleviate. According to Figure 1, its chemical formula is

5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidiny)methyl]-2-methoxybenzamide. The Merck Index includes it.2) No pharmacopoeia recognizes it as an official ingredient.

By inhibiting the pre-synaptic dopamine synthesis and release, levosulpiride acts as a D2-dopamine antagonist, which, at low dosages, enhances the

dopaminergic neurotransmission.(3) Functional dyspepsia, psychosis, and depression are common indications for its prescription. Tonini et al. tested the racemic activity and found that the Levo version was more active. Levosulpiride toxicity was investigated by Lozano et al.(5) The UV Spectrophotometric and RP-HPLC methods for estimating levosulpiride in both bulk drug and formulation were established by Silambaresan et al.(6) It is the aim of this research to provide analytical techniques for the bulk and formulation determination of levosulpiride that are easy to use, sensitive, accurate, economical, and specific.

Department of Pharmacy

Ratnam Institute of Pharmacy, Pidathapalur (V), Muthukur (M), SPSR Nellore Dt.524001 A.P. India

Materials and Methods

Sun Pharmaceuticals, Jammu, provided a free, pure sample of levosulpiride. Hydrochloric acid, sodium hydroxide, and methanol are the chemicals utilized, and they are of an analytical quality. Throughout the investigation, a UV-Visible spectrophotometer from Shimadzu, equipped with UV Probe software, was employed.

The sample container was a quartz cell with a 10-millimeter route length. We got the pills from a drugstore down the street. A precise 100 milligrams of the pure sample was dissolved in 100 milliliters of the corresponding solvents at a concentration of 1 milligram per milliliter. The appropriate solvents were used to create a stock solution of Levosulpiride at a concentration of 100 µg/ml. Twenty precisely measured and powdered tablets containing 100 mg of levosulpiride equivalent were used in the investigation. Volumes were prepared with the appropriate solvents from aliquots of stock solutions transferred to a series of 10 ml standard flasks for the manufacture of varied concentrations. Levosulpiride in 0.1 N HCl was made at five different concentrations ranging from 20 to 100 µg/ml. Spectroscopy was used to scan the fluid from 400 nm to 200 nm.

In order to determine if a standard solution has a wide or not sharp peak, we may utilize the area under curve (AUC) approach using a UV visible

spectrophotometer. The plotted area beneath the peak is a function of concentration and is computed in square millimeters. That is why λ_1 and λ_2 are chosen as the two wavelengths. The area under the curve may be determined using area computation software within the specified wavelength range. Repeated scanning yields the area for various standard concentrations, which are then plotted against their corresponding concentrations to produce a linear graph. The concentration (20-100 µg/mL) and Area Under the curve (AUC) in the chosen wavelength range were plotted to create a calibration curve.(7)

Validation of the proposed method: The proposed method was validated in terms of linearity, accuracy, precision and ruggedness.

Linearity study: Stock Levosulpiride solution in 0.1N HCl were transferred into series of 10 ml volumetric flasks and the volume was made up to the mark with water to get concentrations 20,40,60,80,100 µg/ml, respectively. These solutions were scanned on spectrometer in the UV range 200-400 nm. The two wavelengths 220 and 288 nm were selected for the determination of Area under Curve (Fig. 2). The calibration plot was constructed as a function of Area under Curve vs. Concentration.




Fig. 1: Area under Curve Spectrum of Levosulpiride in 0.1 N HCl

Accuracy: A known amount of standard stock solution was mixed with the pre-analysed sample at different levels (80%, 100%, 120%). The solutions were analyzed using the proposed method.

Precision: The precision was checked for inter-day and intra-day variation. Intra-day precision was determined by analyzing the 60, 80 and 100 µg/ml of drug solutions for three times on the same day. Inter-day precision of the proposed method was checked by analyzing the 60, 80 and 100 µg/ml of Levosulpiride for three different days.

Sensitivity: The sensitivity of the proposed method for the measurements of Levosulpiride was estimated by using Limit of Detection (LOD) and Limit of Quantification (LOQ). The LOQ and LOD were calculated using $LOD = 3.3 \times N/B$ and $LOQ = 10 \times N/B$, where N is standard deviation of the peak areas of the drugs ($n=3$), taken as a measure of noise, and B is the slope of the standard curve.

Repeatability: On analyzing 40 µg/ml concentration of Levosulpiride solution for six times repeatability of this method was established.

Ruggedness:The determination of Ruggedness of the proposed method was studied by analyzing 40µg/ml of drug by two analysts under the similar environmental and operational conditions.

Determination of Levosulpiride in Bulk
100mg of Levosulpiride was weighed accurately and transferred to a 100ml volumetric flask, diluted the mixture with 0.1N HCl. The whole solution was filtered through a Whatman filter paper no: 42. From the filtrate, make up a final solution of concentration of 60µg/ml. The resulting solution was scanned on a spectrophotometer in the UV range 200-400nm. The concentrations of the drug were calculated from linear regression equations.

Application of the developed method for pharmaceutical formulation: For analysis of the commercial formulation 100mg of levosulpiride was

transferred to a 100ml volumetric flask and 50 ml 0.1N HCl was added. After ultrasonication for 15 minutes. The mixture was diluted up to the mark with

0.1 N HCl. The whole solution was filtered through a Whatman filter paper no: 42. From filtrate correct dilution were taken in such a way that the final concentration is 60µg/ml. The concentrations of the drug were calculated from linear regression equations. The resulting solution was scanned on a spectrophotometer in the UV range 200-400nm.

Results and Discussion


Method validation: The developed method was validated in accordance with ICH guidelines. Drug solutions with different concentrations are prepared as per the procedure described in the experiment.

Linearity studies: The linear regression data of Area under curve versus concentration gives a linear relationship at the range of 20-100µg/ml for levosulpiride (Fig.3). Linear regression equation was found to be $Y = 0.10552 X + 0.04080$. (Table 1) with a correlation coefficient of $r^2 = 0.9992$.

Standard Table Report

10/10/2016 10:33:31 PM

File Name: C:\Program Files\Shimadzu\UVProbe\Data\levosulp Hcl new stndrd curve.pho



Sample ID	Type	Ex	Conc	WL800.0_400.0	Wgt.Factor	Comments
1	Standard		20.000	2.115	1.000	
2	Standard		40.000	4.289	1.000	
3	Standard		60.000	6.397	1.000	
4	Standard		80.000	8.495	1.000	
5	Standard		100.000	10.564	1.000	
6						

Fig.2: Calibration curve of levosulpiride

Accuracy: Recovery studies at 80,100,120% of the pre-analysed samples show that the % recovery was between 99-101%. (Table 2)

Precision: The precision of proposed method expressed in %RSD and the value was found to be less than 2. This indicates that the method is precise and can be used for the determination of both drugs in formulation and shows the reproducibility of the assay. (Table 3)

Sensitivity: The LOD and LOQ were found to be 0.9479 and 2.8724µg, respectively (Table 4).

Repeatability: Repeatability was determined by analyzing 60 µg/ml concentration of Levosulpiride (6 times) and the % RSD was found to be less than 2 (Table 5).

Ruggedness: Peak Area measurement of six concentrations of drug shows that the % RSD was found to be less than 2% (Table 6).

of drug shows that the % RSD was found to be less than 2% (Table 6).

Determination of Levosulpiride in bulk: The concentrations of the drug was calculated from Area under Curve versus Concentration Linear regression equation.

The percentage amount was found in between 98.00% to 102.002% (Table 7).

Application of developed method on formulations: The concentrations of the drug in a marketed formulation (Nexipride) was calculated from Area

under Curve versus Concentration Linear regression equations. The percentage amount was found in between 98.00% to 102.002% (Table 8).

Table1:Linearitystudies

Concentration µg/mL	Area, ^a mean±SD(n=6)	%RSD
20	2.115±0.0148	0.28
40	4.289±0.0101	0.10
60	6.397±0.0458	0.37
80	8.495±0.0438	0.20
100	10.564±0.0622	0.20

(n=no.ofestimations)

Table2: Recoverystudies

Drug	Initialamo unt(µg/mL)	Amount added(µg/ mL)	Amountrecovery d(µg/mL,n=3)	% recovered	%RSD
Levosulpiride	40	32	31.9351	99.7972	0.6526
	40	40	40.2342	100.5855	0.4855
	40	48	48.0809	100.168	0.8570

(n=no.ofestimations)

Table3:ResultsofPrecision studies

Component	Concentration (µg/mL)	Intra-dayprecision ^a (n=3)		Inter-dayprecision ^a (n=3)	
		Amt.found	%RSD	Amt.found	%RSD
Levosulpiride	40	40.0461	0.4860	39.9351	0.6526
	60	60.0809	0.8570	60.1208	0.2526
	80	80.2127	0.4192	80.1387	0.6109

^aAverageofthreeestimation

Table4:SensitivityStudies

LOD(µg/mL)	LOQ(µg/mL)
0.9479	2.8724

Table5:RepeatabilityStudies

Sample	Amount taken(µg/mL) (n=6)	Amountfoundin ^a %	%RSD
Levosulpiride	60	99.33±0.24	0.26

^aAverageofsixestimation

Table6: Ruggedness study

Component	Amount taken(µg/mL) (n=6)	Amountfound ^a (%)		%RSD	
		AnalystI±SD	AnalystII ±SD	AnalystI	AnalystII
Levosulpiride	60	100±0.5083	100±0.7413	0.5047	0.7372

^aAverageofsixestimation

Table7:AnalysisofLevosulpiridein bulk

Concentration inµg/mL	Amountf ound(µg)	Amount foundin %
60	59.8578	99.4076
	59.5844	98.2682
	59.8891	99.5378
	59.7953	99.1471
	59.8656	99.4401
	59.7406	98.9193

mean±SD	59.7888±0.4746	99.1200±0.4746
%RSD	0.4788	0.4788

Table8: Analysis of Levosulpiride in formulation (Nexipride 100mg, sunpharma)

Concentration(µg/mL)	Amount found(µg)	Amount found(%)
60	59.8578	99.4076
	59.7797	99.0820
	59.8109	99.2122
	59.8422	99.3424
	59.8344	99.3099
	59.8188	99.2488
mean±SD	59.8240 ±0.110	99.2665 ±0.1140
%RSD	0.1149	0.1149

Conclusion

Simple, accurate, sensitive, and repeatable—those are the hallmarks of the UV Spectrophotometric approach. Using this procedure, the amount of levosulpiride in the formulation has been measured. It is a suitable and accurate quantification approach that is used for routine quality control of compounds in bulk and formulations, according to the validation procedure.

development and validation of Rizatriptan benzoate. International journal of pharmaceutical chemistry and analysis 2016;3(1):13-17.

Acknowledgements

The Authors are grateful for providing pure Levosulpiride as gift sample from SUNPHARMA, Jammu.

Conflict of interest: Nil

Source of support: Nil

References

1. View the Levosulpiride page on the druginfo sys website.
2. The Merck Index, 1542, 14th edition, Merck & Co., Inc. Encyclopedia of Chemicals, Drugs, and Biologicals, 2006-.
3. Levosulpiride: A review of its clinical usage in psychiatry by Mucci A, Nolf G, and Maj M. Pharmaceutical Research 1995;31:95-101. Tonini M, Cipollina L, Pouzzie, Crema F, Corazza G, DePonti F. Clinical implications of enteric and central D2 receptor blockade by antiparkinsonian gastrointestinal prokinetics. Alimentary Pharmacology and Therapeutics, 2004;19:379-90.
4. Lozano R, Peralta Concha M, Montealegre A, de Leon A, Ortiz Villalba J, Ensteban H, et al. Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. Therapeutics and clinical Risk Management 2007;3:149-155.
5. Silambarasan S P, Anandakumar K, Venkatalakshmi R, Sasikal C. Development of UV Spectrophotometry and RP-HPLC methods for the estimation of Levosulpiride in bulk and tablet formulation. Asian J Res Chem 2010;03(3):542.
6. Pritam S, Jain, Harshal P, Chaudhari, Pankaj R, Bari, Sanjay J. Surana. Area under curve method